936901-82-5Relevant academic research and scientific papers
Imidazo[1,5-a]pyrazines: Orally efficacious inhibitors of mTORC1 and mTORC2
Crew, Andrew P.,Bhagwat, Shripad V.,Dong, Hanqing,Bittner, Mark A.,Chan, Anna,Chen, Xin,Coate, Heather,Cooke, Andrew,Gokhale, Prafulla C.,Honda, Ayako,Jin, Meizhong,Kahler, Jennifer,Mantis, Christine,Mulvihill, Mark J.,Tavares-Greco, Paula A.,Volk, Brian,Wang, Jing,Werner, Douglas S.,Arnold, Lee D.,Pachter, Jonathan A.,Wild, Robert,Gibson, Neil W.
scheme or table, p. 2092 - 2097 (2011/04/24)
The discovery and optimization of a series of imidazo[1,5-a]pyrazine inhibitors of mTOR is described. HTS hits were optimized for potency, selectivity and metabolic stability to provide the orally bioavailable proof of concept compound 4c that demonstrate
Fused bicyclic mTOR inhibitors
-
Page/Page column 66-67, (2008/06/13)
Compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, are inhibitors of mTOR and useful in the treatment of cancer.
UNSATURATED mTOR INHIBITORS
-
Page/Page column 48, (2010/11/28)
Compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, are inhibitors of mTOR and useful in the treatment of cancer.
